08:14 AM EST, 11/06/2024 (MT Newswires) -- Crescita Therapeutics ( CRRTF ) on Wednesday reported a narrower third quarter net loss as revenue jumped 18%.

The net loss fell to $1.03 million from $1.3 million last year.

Revenue climbed to $3.6 million.

"Our year-over-year revenue growth of 18.5% in the third quarter reflects organic and inorganic growth in our Skincare segment, and higher licensing revenue from supplying Pliaglis in support of international launches," said Serge Verreault, President and CEO. "We expect to see continued improvement in our Manufacturing segment as we integrate new manufacturing equipment into our plant and begin to fulfill the recently announced new long-term manufacturing and supply agreements.